24-hour powerful blood pressure-lowering: is there a clinical need?

Journal of the American Society of Hypertension

Volumn 2, Issue 4 SUPPL., 2008, Pages

  McInnes, Gordon ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

blood pressure control; Early morning blood pressure surge; smoothness index; telmisartan

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS HYDROCHLOROTHIAZIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPROSARTAN; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS TELMISARTAN; IRBESARTAN; LOSARTAN; OLMESARTAN; RAMIPRIL; TELMISARTAN; VALSARTAN;

ARTICLE; BLOOD PRESSURE FLUCTUATION; BLOOD PRESSURE REGULATION; BLOOD PRESSURE VARIABILITY; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; HUMAN; HYPERTENSION; LIPOPHILICITY; MONOTHERAPY; MORNING DOSAGE; PRIORITY JOURNAL; PROGNOSIS; RECOMMENDED DRUG DOSE; STRUCTURE ACTIVITY RELATION;

EID: 46849116407     PISSN: 19331711     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jash.2008.03.004     Document Type: Article

References (39)

1. Millar-Craig M.W., Bishop C.N., and Raftery E.B. Circadian variation of blood-pressure. Lancet 1 (1978) 795-797
2. Mancia G., Ferrari A., Gregorini L., Parati G., Pomidossi G., Bertinieri G., et al. Blood pressure and heart rate variabilities in normotensive and hypertensive human beings. Circ Res 53 (1983) 96-104
3. Parati G., Pomidossi G., Albini F., Malaspina D., and Mancia G. Relationship of 24-hour blood pressure mean and variability to severity of target organ damage in hypertension. J Hypertens 5 (1987) 93-98
4. Palatini P., Penzo M., Racioppa A., Zugno E., Guzzardi G., Anaclerio M., et al. Clinical relevance of night-time blood pressure and of day-time blood pressure variability. Arch Intern Med 152 (1992) 1855-1860
5. Sander D., and Klingelhofer J. Diurnal systolic blood pressure variability is the strongest predictor of early carotid atherosclerosis. Neurology 47 (1996) 500-507
6. Goldstein I.B., Bartzokis G., Hance D.B., and Shapiro D. Relationship between blood pressure and subcortical lesions in healthy elderly people. Stroke 29 (1998) 765-772
7. Mancia G., Parati G., Hennig M., Flatau B., Omboni S., Glavina F., et al. Relation between blood pressure variability and carotid artery damage in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis (ELSA). J Hypertens 19 (2001) 1981-1989
8. Frattola A., Parati G., Cuspidi C., Albini F., and Mancia G. Prognostic value of 24-hour blood pressure variability. J Hypertens 11 (1993) 1133-1137
9. Pickering T.G., and James G.D. Ambulatory blood pressure and prognosis. J Hypertens Suppl 12 (1994) S29-S33
10. Sander D., Kukla C., Klingelhofer J., Winbeck K., and Conrad B. Relationship between circadian blood pressure patterns and progression of early carotid atherosclerosis: a 3-year follow-up study. Circulation 102 (2000) 1536-1541
11. Marler J.R., Price T.R., Clark G.L., Muller J.E., Robertson T., Mohr J.P., et al. Morning increase in onset of ischemic stroke. Stroke 20 (1989) 473-476
12. Muller J.E., Stone P.H., Turi Z.G., Rutherford J.D., Czeisler C.A., Parker C., et al. Circadian variation in the frequency of onset of acute myocardial infarction. N Engl J Med 313 (1985) 1315-1322
13. Rocco M.B., Barry J., Campbell S., Nabel E., Cook E.F., Goldman L., et al. Circadian variation of transient myocardial ischemia in patients with coronary artery disease. Circulation 75 (1987) 395-400
14. Kario K., Pickering T.G., Umeda Y., Hoshide S., Hoshide Y., Morinari M., et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation 107 (2003) 1401-1406
15. Gosse P., Lasserre R., Minifie C., Lemetayer P., and Clementy J. Blood pressure surge on rising. J Hypertens 22 (2004) 1113-1118
16. Redon J., Roca-Cusachs A., and Mora-Macia J. Uncontrolled early morning blood pressure in medicated patients: the ACAMPA study. Analysis of the control of blood pressure using ambulatory blood pressure monitoring. Blood Press Monit 7 (2002) 111-116
17. Manfredini R., Boari B., and Portaluppi F. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives. Circulation 108 (2003) e72-e73 author reply e72-3
18. Lipicky R.J. Trough: peak ratio: the rationale behind the United States Food and Drug Administration recommendations. J Hypertens Suppl 12 (1994) S17-S18
19. Neutel J.M. Ambulatory blood pressure monitoring to assess the comparative efficacy and duration of action of a novel new angiotensin II receptor blocker-telmisartan. Blood Press 10 (2001) S27-S32
20. Parati G., Omboni S., Rizzoni D., Agabiti-Rosei E., and Mancia G. The smoothness index: a new, reproducible and clinically relevant measure of the homogeneity of the blood pressure reduction with treatment for hypertension. J Hypertens 16 (1998) 1685-1691
21. Parati G., Schumacher H., and Mancia G. Evaluating 24-hour antihypertensive efficacy by the smoothness index: a meta-analysis of an ambulatory blood pressure monitoring database. (abstract). J Hypertens 24 (2006) S301
22. Rizzoni D., Muiesan M.L., Salvetti M., Castellano M., Bettoni G., Monteduro C., et al. The smoothness index, but not the trough-to-peak ratio predicts changes in carotid artery wall thickness during antihypertensive treatment. J Hypertens 19 (2001) 703-711
23. Zhu J.R., Bai J., Cai N.S., Tang B., Fan W.H., Guo J.Z., et al. Efficacy and safety of telmisartan vs. losartan in control of mild-to-moderate hypertension: a multicentre, randomised, double-blind study. Int J Clin Pract Suppl 145 (2004) 46-49
24. Lee Y.T., Lee C.M., Lin C.S., Sheu S.H., Kuo W.K., Tsai C.W., et al. A double-blind comparison of the efficacy and tolerability of telmisartan 40-80 mg vs. losartan 50-100 mg in Taiwanese hypertensive patients. Int J Clin Pract Suppl 145 (2004) 40-45
25. White W.B., Lacourciere Y., and Davidai G. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure. Am J Hypertens 17 (2004) 347-352
26. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., and Dagenais G. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study investigators. N Engl J Med 342 (2000) 145-153
27. Williams B., Gosse P., Lowe L., Harper R., and PRISMA I Study Group. The prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMA I). J Hypertens 24 (2006) 193-200
28. Lacourciere Y., Neutel J.M., Davidai G., and Koval S. A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring. Am J Hypertens 19 (2006) 104-112
29. Gosse P., Neutel J.M., Schumacher H., Lacourciere Y., Williams B., and Davidai G. The effect of telmisartan and ramipril on early morning blood pressure surge: a pooled analysis of two randomized clinical trials. Blood Press Monit 12 (2007) 141-147
30. Van Zwieten P.A. The pharmacological properties of lipophilic calcium antagonists. Blood Press Suppl 2 (1998) 5-9
31. Lacourciere Y., Lenis J., Orchard R., Lewanczuk R., Houde M., Pesant Y., et al. A comparison of the efficacies and duration of action of the angiotensin II receptor blockers telmisartan and amlodipine. Blood Press Monit 3 (1998) 295-302
32. Lacourciere Y., Krzesinski J.M., White W.B., Davidai G., and Schumacher H. Sustained antihypertensive activity of telmisartan compared with valsartan. Blood Press Monit 9 (2004) 203-210
33. Neldam S., Edwards C., and ATHOS Study Group. Telmisartan plus HCTZ vs. amlodipine plus HCTZ in older patients with systolic hypertension: results from a large ambulatory blood pressure monitoring study. Am J Geriatr Cardiol 15 (2006) 151-160
34. Kakuta H., Sudoh K., Sasamata M., and Yamagishi S. Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers. Int J Clin Pharmacol Res 25 (2005) 41-46
35. Wienen W., Hauel N., Van Meel J.C., Narr B., Ries U., and Entzeroth M. Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277. Br J Pharmacol 110 (1993) 245-252
36. Burnier M., and Brunner H.R. Angiotensin II receptor antagonists. Lancet 355 (2000) 637-645
37. Brunner H.R. The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview. J Hum Hypertens 16 (2002) S13-S16
38. Wienen W., Entzeroth M., Van Meel J.C.A., Stangier J., Busch U., Ebner T., et al. A review on telmisartan: a novel, long-acting angiotensin II-receptor antagonist. Cardiovasc Drug Rev 18 (2000) 127-156
39. Song J.C., and White C.M. Olmesartan medoxomil (CS-866). An angiotensin II receptor blocker for treatment of hypertension. Formulary 36 (2001) 487-499